Caplin Steriles gets USFDA approval for Norepinephrine Bitartrate Injection

Caplin Steriles Limited (Caplin), a Subsidiary Company of Caplin Point Laboratories Limited (BSE: CAPPL (524742), NSE: CAPLIPOINT), has been granted final approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Norepinephrine Bitartrate Injection USP, 4 mg/4 mL (1 mg/mL) Single-Dose Vial, a generic therapeutic equivalent version of (RLD), LEVOPHED injection of Hospira Inc.

Norepinephrine Bitartrate Injection is used for restoration of blood pressure in adult patients with acute hypotensive states. According to IQVIATM (IMS Health), Norepinephrine Bitartrate Injection USP had US sales of approximately $40 million for the 12-month period ending June 2023.

Shares of Caplin Point Laboratories Limited was last trading in BSE at Rs. 1041.70 as compared to the previous close of Rs. 1044.45. The total number of shares traded during the day was 6112 in over 654 trades.

The stock hit an intraday high of Rs. 1056.90 and intraday low of 1023.60. The net turnover during the day was Rs. 6385552.00.

Source : Equity Bulls

Keywords

CaplinPointLaboratories INE475E01026 CaplinSteriles FinalApproval USFDA NADA NorepinephrineBitartrateInjection